Hong Kong University of Science and Technology licenses MDL® software
MDL® Assay Explorer® and other MDL solutions support drug discovery research at a leading university in China
San Ramon, CA and Kowloon, HONG KONG — June 12, 2007 — Hong Kong University of Science and Technology (HKUST) has licensed the MDL® Assay Explorer® biological data management system along with the MDL® ChemBio AE and MDL® Report Manager applications. Scientists at the university’s Biotechnology Research Institute (BRI) will use these MDL solutions while researching novel molecular targets associated with therapeutics and diagnostics used in the detection and treatment of neurological diseases.
BRI offers a world-class research infrastructure dedicated to fostering cooperation among academia, industry and government. The Institute is committed to excellence in innovative research with a focus on neuroscience, protein engineering and design, signal transduction and knowledge-based drug discovery and development programs in traditional Chinese medicine ( www.ust.hk/en/index.html).
"For years, Elsevier MDL has been known as the leader in cheminformatics data management," said Dr. Maurice K. C. Ho, Senior Scientific Officer at BRI/HKUST. "Because most of our current collaborators also use MDL products, the migration to MDL solutions facilitates a nearly failure-free and transparent data exchange and consolidation with our partners. Elsevier MDL’s recent successful development of more versatile bioassay data management solutions also influenced this move. With the implementation of MDL Assay Explorer, we now have a complete and expandable data exchange platform for different working teams in our institute. As an example, the application has greatly facilitated BRI’s collaboration with the US-based Geron Corporation in the identification and development of novel drug candidates."
"MDL software will facilitate successful interdisciplinary collaboration at the Biotechnology Research Institute of HKUST by integrating chemical and biological data and supporting enterprise-wide reporting," said Elsevier MDL President and CEO, Lars Barfod. "Elsevier MDL is committed to supporting important life sciences research around the world, and we are delighted that HKUST has elected to license MDL software to support its groundbreaking work in science."
NeoTrident Technology LTD, Elsevier MDL’s Chinese distributor, will provide HKUST with full product support including implementation, training and customer service ( www.neotrident.com). For more information about Elsevier MDL, contact your Elsevier MDL account manager or visit www.mdl.com.
# # #
Hong Kong University of Science and Technology (HKUST), located in Kowloon, Hong Kong, is a dynamic, international research university in relentless pursuit of excellence, leading the advance of science and technology, and educating the new generation of front-runners for Asia and the world. Since its official opening in October 1991, HKUST has established itself as an intellectual powerhouse, energizing the community's transformation into a knowledge-based society, and securing a place on the academic world map in record-breaking time.
An innovator in research and teaching, HKUST is the only science and technology research university in Hong Kong, and the only one to offer an all-PhD faculty. Its groundbreaking work in science, engineering, business, humanities and social science is successfully pushing back the boundaries of the information age. Such advances are assisted by the University's top-class facilities. There are approximately 8,800 students and 430 faculty on the 150-acre campus located on the Clear Water Bay peninsula in East Kowloon. For more information, visit www.ust.hk/en/index.html.
About Elsevier MDL
Elsevier MDL provides informatics, database and workflow solutions that accelerate successful scientific R&D by improving the speed and quality of scientists’ decision making. Researchers around the world depend on Elsevier MDL for innovative and reliable discovery informatics software solutions and services augmented by 400 Elsevier chemistry and life sciences journals and related products. For more information, visit www.mdl.com. Elsevier is a world-leading publisher of scientific, technical and medical information products and services. For more information, visit www.elsevier.com.
Elsevier is part of Reed Elsevier Group plc, a world-leading publisher and information provider. Reed Elsevier's ticker symbols are REN (Euronext Amsterdam), REL (London Stock Exchange), RUK and ENL (New York Stock Exchange). For more information, visit www.reedelsevier.com.
Elsevier is a world-leading provider of information solutions that enhance the performance of science, health, and technology professionals, empowering them to make better decisions, deliver better care, and sometimes make groundbreaking discoveries that advance the boundaries of knowledge and human progress. Elsevier provides web-based, digital solutions — among them ScienceDirect, Scopus, Research Intelligence and ClinicalKey— and publishes over 2,500 journals, including The Lancet and Cell, and more than 35,000 book titles, including a number of iconic reference works. Elsevier is part of RELX Group, a world-leading provider of information and analytics for professional and business customers across industries. www.elsevier.com